Soman induces ictogenesis in the amygdala and interictal activity in the hippocampus that are blocked by a GluR5 kainate receptor antagonist in vitro
about
α-Linolenic Acid, A Nutraceutical with Pleiotropic Properties That Targets Endogenous Neuroprotective Pathways to Protect against Organophosphate Nerve Agent-Induced NeuropathologyLY293558 prevents soman-induced pathophysiological alterations in the basolateral amygdala and the development of anxiety.The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302.Presynaptic facilitation of glutamate release in the basolateral amygdala: a mechanism for the anxiogenic and seizurogenic function of GluK1 receptors.RDX binds to the GABA(A) receptor-convulsant site and blocks GABA(A) receptor-mediated currents in the amygdala: a mechanism for RDX-induced seizures.Benzodiazepine site agonists differentially alter acetylcholine release in rat amygdala.Higher susceptibility of the ventral versus the dorsal hippocampus and the posteroventral versus anterodorsal amygdala to soman-induced neuropathology.The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.Neuroprotective efficacy of caramiphen against soman and mechanisms of its action.A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonistsPathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis.Primary brain targets of nerve agents: the role of the amygdala in comparison to the hippocampus.The M1 Muscarinic Receptor Antagonist VU0255035 Delays the Development of Status Epilepticus after Organophosphate Exposure and Prevents Hyperexcitability in the Basolateral Amygdala.Evaluation of acetylcholine, seizure activity and neuropathology following high-dose nerve agent exposure and delayed neuroprotective treatment drugs in freely moving rats.
P2860
Q26777019-5F54D19E-02A2-411A-AD95-C98493D477F0Q30392504-529FC6DA-7011-49EC-9047-6D81A43FA540Q30399944-DDC1FA3D-0D49-4CC1-9218-C51BD623991FQ30448913-E11A30E9-23E4-4CDC-BBFB-5B5F22C5C68CQ30476265-D84FD000-9864-4FAF-A461-7D1F22AFE1BBQ33745836-04016EBB-2A16-43A5-9A8A-36650B354808Q34106485-3926316F-E7FA-438E-B1EE-722EC94A3BBAQ34552059-7BA07451-C861-4B95-BF01-CB8ED98A75E0Q35564288-62F9B689-7B3D-4F13-8DDC-A31DBD34FA6EQ35985022-72A230FB-7050-4EE7-A97E-F47D488C166DQ37323385-C8989260-EA44-404A-AEBA-C3F01E724829Q37386453-8C2984BD-D806-42E2-B0C7-FFBD4456285EQ48448168-E50E31CB-9231-48C5-B31E-1F84D39E3088Q48663292-35CB183C-33DC-48DD-BB10-7D84DB24898B
P2860
Soman induces ictogenesis in the amygdala and interictal activity in the hippocampus that are blocked by a GluR5 kainate receptor antagonist in vitro
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@ast
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@en
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@nl
type
label
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@ast
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@en
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@nl
prefLabel
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@ast
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@en
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@nl
P2093
P2860
P1433
P1476
Soman induces ictogenesis in t ...... e receptor antagonist in vitro
@en
P2093
J P Apland
M F M Braga
V Aroniadou-Anderjaska
P2860
P304
P356
10.1016/J.NEUROSCIENCE.2008.11.053
P407
P577
2008-12-14T00:00:00Z